AssayIndex
Incretin analogues and co-agonists

Cagrilintide

AM833 · long-acting amylin analogue · C194H310N54O61 · monoisotopic 3961.3218 Da. The index holds 32 assay reports on this compound across 8 batches from 5 suppliers.

32 reports8 batchesmedian 98.59 %index spec 96.5 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Cagrilintide carries a Cys2–Cys7 disulfide, and almost everything analytically interesting about it follows from that. The reduced open-chain form at +2 Da elutes 1.2 min early and is the most common impurity in poorly handled lots; a scrambled isomer is mass-identical and only resolves on RG-2's full 30-min gradient. Because reduction is a handling artefact, the index flags any cagrilintide report where the open-chain form exceeds 1.5 % area for cold-chain review rather than counting it against the synthesis. Coverage is thin — n is under 90 across the whole index — so per-supplier medians for cagrilintide carry a low-n caveat everywhere they appear. Base peak [M+4H]4+ at m/z 991.34.

Molecular formula
C194H310N54O61
Monoisotopic mass
3961.3218Da
Average mass
3963.65Da
Residues
32
Nominal retention (RG-2, 30 min)
16.74min
Retention window
0.45min
Counter-ion as usually shipped
TFA
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
1.35 — moderate
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

01590318147716361 Cagrilintide16.74 min · 98.59 % 13.1215.5320.18 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Cagrilintide trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.59 % area at the nominal retention time of 16.74 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 32 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.59% n=32
Interquartile range 1.24pp n=32
Minimum 97.46% n=32
Maximum 99.91% n=32
Pass rate vs spec 100.0% n=32
Median recovery vs claim 98.5% n=21
Median water 4.17% n=32
Median |mass error| 3.1ppm n=25
024692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=197.50–97.75 %: n=297.75–98.00 %: n=698.00–98.25 %: n=498.25–98.50 %: n=298.50–98.75 %: n=398.75–99.00 %: n=299.00–99.25 %: n=499.25–99.50 %: n=499.50–99.75 %: n=399.75–100.00 %: n=1median 98.59 Purity (% area) Reports
Figure 2. Purity distribution across all 32 Cagrilintide records. Dashed line is this compound's median (98.59 %); the solid vertical is the index acceptance specification for the incretin analogues and co-agonists class (96.5 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.397.798.298.799.299.6100.1GGPepsGGPeps: Q1 97.77, median 98.10, Q3 98.33, n=13outlier 99.28n=13BCHBCH: Q1 98.14, median 99.11, Q3 99.46, n=12n=12FGPFGP: Q1 98.44, median 98.73, Q3 99.03, n=4n=4JEEPJEEP: Q1 99.50, median 99.54, Q3 99.58, n=2n=2 Purity (% area)
Figure 3. Cagrilintide purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
cagrilintide dimer (intermolecular disulfide)+3.44+3959.306100%0.111.08
des-C16 diacid (−254 Da)-3.62-254.22597%0.291.07
open-chain (reduced disulfide, +2 Da)-1.21+2.01694%0.141.83
disulfide-scrambled isomer+0.48mass-identical94%0.151.30
deamidated (+1 Da)-0.44+0.98491%0.110.82

Degradation pathways

  • disulfide scrambling above pH 7.5 — the main stability liability
  • aggregation of the open-chain form, which nucleates fibrils rapidly

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Cagrilintide is studied both alone and co-formulated with semaglutide as CagriSema; phase 2 data appeared in Lancet (2021). No approved product exists.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q2698.0697.59–99.91
2024-Q30n<3—
2024-Q4398.5997.98–98.68
2025-Q10n<3—
2025-Q20n<3—
2025-Q30n<3—
2025-Q41498.6997.60–99.72
2026-Q10n<3—
2026-Q2998.8897.46–99.61
2026-Q30n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Cagrilintide records of 32.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041747FGPFGP-2602-M9870Nordanalyt2026-Q298.033.83—Supplier-supplied0PASS
AX-2026-041749FGPFGP-2602-M9870Janoshik2026-Q299.474.14—Supplier-supplied0PASS
AX-2026-042749GGPepsGGPE-2603-R9581Medutest2026-Q297.956.05—Supplier-supplied1FAIL
AX-2026-041877JEEPJEEP-2603-E3844Janoshik2026-Q299.616.44—Supplier-supplied0PASS
AX-2026-042386SWBSWB-2601-J5083Janoshik2026-Q299.154.21101.5Supplier-supplied0PASS
AX-2026-041876JEEPJEEP-2603-E3844PeptideMeter2026-Q299.476.11—Supplier-supplied1MARGINAL
AX-2026-041748FGPFGP-2602-M9870PeptideMeter2026-Q298.884.0199.6Supplier-supplied0PASS
AX-2026-041750FGPFGP-2602-M9870Medutest2026-Q298.583.4393.1Supplier-supplied0PASS
AX-2026-042750GGPepsGGPE-2603-R9581Janoshik2026-Q297.465.3198.5Supplier-supplied0PASS
AX-2026-042791GGPepsGGPE-2507-Y1706Janoshik2025-Q498.101.04105.5Supplier-supplied1MARGINAL
AX-2025-020224GGPepsGGPE-2507-Y1706PeptideMeter2025-Q498.331.24107.5Supplier-supplied1MARGINAL
AX-2025-021258BCHBCH-2509-A6666Nordanalyt2025-Q499.195.44105.3Supplier-supplied1MARGINAL
AX-2025-020227GGPepsGGPE-2507-Y1706Janoshik2025-Q497.760.9391.6Supplier-supplied2MARGINAL
AX-2025-020229GGPepsGGPE-2507-Y1706Kestrel2025-Q499.281.9393.6Supplier-supplied2MARGINAL
AX-2025-021254BCHBCH-2509-A6666Nordanalyt2025-Q499.425.7493.4Supplier-supplied1MARGINAL
AX-2025-021255BCHBCH-2509-A6666PeptideMeter2025-Q499.186.77—Supplier-supplied1MARGINAL
AX-2025-020228GGPepsGGPE-2507-Y1706Janoshik2025-Q497.771.4790.7Supplier-supplied1MARGINAL
AX-2025-020226GGPepsGGPE-2507-Y1706Medutest2025-Q498.251.5991.5Supplier-supplied1MARGINAL
AX-2025-020225GGPepsGGPE-2507-Y1706Janoshik2025-Q497.601.6299.7Supplier-supplied1MARGINAL
AX-2025-021259BCHBCH-2509-A6666Medutest2025-Q499.726.1695.7Supplier-supplied1MARGINAL
AX-2025-020230GGPepsGGPE-2507-Y1706Janoshik2025-Q498.221.64—Supplier-supplied1MARGINAL
AX-2025-021256BCHBCH-2509-A6666Medutest2025-Q499.046.4792.6Supplier-supplied1MARGINAL
AX-2025-021257BCHBCH-2509-A6666Janoshik2025-Q499.575.99107.0Supplier-supplied1MARGINAL
AX-2024-004974GGPepsGGPE-2410-U9081Janoshik2024-Q498.595.23—Supplier-supplied1MARGINAL
AX-2024-004972GGPepsGGPE-2410-U9081Janoshik2024-Q497.985.89—Supplier-supplied1MARGINAL